BioFinlandin jäsen

Vactech develops and licenses vaccines and novel technologies for vaccines and diagnostics. Our pipeline includes Type 1 Diabetes vaccine, a vaccine against Asthma and Allergy and a VLP technology platform IMAVAC™ suitable for applications like vaccines, adjuvants, delivery vehicles and diagnostics.

Vactech’s flagship project is a patented enterovirus based preventive Type 1 Diabetes (T1D) vaccine, similar to the widely used enterovirus vaccine against polio. The prevalence of T1D is rapidly increasing. With modest target and penetration parameters the revenue of the vaccine is expected to be more than 5 billion dollars only in US and EU during the first 10 years following the market introduction.

Vactech is a privately owned company which has engaged in a strategic partnership with Provention Bio, Inc. especially in the field of T1D vaccine, see www.proventionbio.com for additional information.